Prestige Consumer Healthcare Inc. (PBH): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Prestige Consumer Healthcare Inc. (PBH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 10, 2026, Jeffrey Zerillo notified Prestige Consumer Healthcare Inc. (the “Company”) of his decision to retire fr

Event · Exec change
Person
Jeffrey Zerillo
Title
Senior Vice President, Operations
Action
retired
Effective
August 14, 2026

Facts are quoted from the filing text and checked against it.

Original reporting
Published Aug 14, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$PBH
Neutral
medium confidence
Mentioned
$PBH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PBHNeutralLow
01

Why it matters

This is a governance and leadership continuity disclosure. Without disclosed replacement terms or operational changes, it is more relevant for monitoring succession than for repricing near-term earnings power.

02

Market read

Traders may watch for follow-on disclosures naming a successor or detailing compensatory arrangements, but the provided text alone does not change fundamentals.

03

What to watch

The filing references compensatory arrangements and director/officer appointments, but the provided text does not include specifics, so the true market impact may depend on details omitted from the scrape.

Relevance 6/10Novelty 3/10Timing: effective Aug. 14, 2026 for the operations SVP retirement, filed Aug. 14, 2026

Background

The company filed an SEC Form 8-K (Item 5.02) covering departure of a senior officer and related board/officer actions and compensatory arrangements.

Company-level read

Ticker impact

$PBHNeutralMedium confidence
Context

Prestige Consumer Healthcare disclosed in an 8-K that SVP Operations Jeffrey Zerillo will retire effective Aug. 14, 2026.

Expected impact

Likely limited immediate impact; any move would be sentiment-driven around succession rather than fundamentals.

Evidence & confidence

The filing confirms a retirement and effective date, but does not include replacement details, restructuring, or financial targets that would directly reset valuation.

Market effects

Minimal sector read-through; this is company-specific leadership turnover without disclosed operational or regulatory changes.

No clear regional spillover indicated by the filing.

No global catalyst described beyond internal management changes.

Counterpoint

The retirement could be routine succession planning and may not signal operational risk; traders may overreact to the headline without replacement or restructuring details.

Key entities

  • Prestige Consumer Healthcare Inc.

    Subject of the 8-K; disclosed retirement of SVP Operations Jeffrey Zerillo effective Aug. 14, 2026.

  • Jeffrey Zerillo

    Senior Vice President, Operations, who notified the company of his retirement effective Aug. 14, 2026.

  • Christine Sacco

    CFO and COO who signed the filing on Aug. 14, 2026.

Related articles

$PBHMed

Prestige Consumer Healthcare Q2 Earnings Call Highlights

Prestige Consumer Healthcare (PBH) lowered its full-year Clear Eyes sales forecast to under $20M, citing production issues. Q3 revenue is expected at $328M with EPS of $1.05. Recent acquisitions Breathe Right and LaCorium contributed $71M in H1 revenue. The company plans to prioritize debt reduction, with net debt at $2.1B. E-commerce sales growth continues at a mid-teens rate.

$PBHMed

Prestige Consumer Healthcare Inc (PBH) (Q2 2027) Earnings Call Highlights: Revenue Surges

Prestige Consumer Healthcare (PBH) reported Q2 2027 revenue growth of 23%, with EBITDA margin at 34%. The company prioritized debt reduction, leaving $90M in share repurchase authorization. Organic brands performed well, with GI brands benefiting from GLP-1 marketing. Women's Health saw slight quarterly growth but year-to-date decline. Acquisitions Breathe Right and Liquorium showed strong early results.

$PBHMedAI 8/10

Prestige Healthcare (PBH) Q2 2027 Earnings Call Transcript

Prestige Healthcare (PBH) reported Q2 2027 earnings, with revenue up 23% to $336.3M, driven by acquisitions and organic growth. Adjusted EPS rose 6% to $1.13. The company integrated Breathe Right and LaCorium, expecting long-term growth. eCommerce sales grew mid-teens, with investments in digital media and content.